Benchmarking the Pharmaceutical Market by Drug Delivery to 2014

Growth from injectables will mitigate the generic-driven decline of the dominant oral drug segment

Delivery technology can readily enhance the therapeutic value of a drug and, in doing so, helps companies add commercial value across all stages of the drug lifecycle. Physiochemical (e.g. controlled release, bioavailability enhancers) and biomolecular (e.g. protein/peptide, lipid vehicle) delivery platforms are the most prevalent in the drug delivery space, while in terms of route of administration, orals and injectables make up more than 80% of the prescription pharmaceutical market, which is also reflected in their prominence in the delivery technology space.

Looking at the leading prescription pharmaceutical companies, Datamonitor expects there to be a shift in market share away from orals and towards injectable drugs out to 2014. Injectables will see an increase in annual sales of $49 billion over 2008– 14, whereas annual sales from oral drugs will decline $10.9 billion. This reflects a number of underlying factors driving each delivery type, such as therapeutic focus, molecule type and lifecycle stage. On the whole, companies overly exposed to oral therapeutics will see weak sales growth over the forecast period, whereas companies positioned in the injectable drug segment will exhibit the fastest growth out to 2014.

Use this new report to:
• Assess how drug delivery has become an ever present feature in the business model of the leading pharmaceutical companies
• Provides an insight into the prominent technology types in the expansive drug delivery segment
• Benchmarks the sales performance of the leading prescription pharmaceutical companies in terms of drug delivery

Click here for more information on our report.

Share this article with your social network, just click below to share now!

Share |

2010 DDP Awards: Pipeline Value Creation Nominee: Zogenix

DosePro™- the world’s first & only single use, easy to use, disposable, needle free injection system that removes the anxiety associated with a fear of needles Zogenix is a showcase example of a Specialty Phama Co with a foundation in Drug Delivery. Since inception in late 2006, Zogenix has raised $170MM in private capital, acquired and developed a unique drug delivery technology in combination with a drug product through full clinical development, NDA approval and U.S. launch. Zogenix drug delivery technology is called – DosePro™- the world’s first & only single use, easy to use, disposable, needle free injection system that removes the anxiety associated with a fear of needles. Zogenix made history in July 2009 when the U.S. FDA-approved the company’s NDA for the very first product ever that utilizes a pre-filled needle-free injection technology for the treatment of migraine and cluster headaches; SUMAVEL DosePro (sumatriptan for injection). A brief list of Zogenix achievements are below:

• Acquired and completed development of the DosePro single use, needle free injection technology.
• In licensed a single entity oral Hydrocodone product for pain that utilizes Elan’s SODAS controlled release drug delivery technology – Phase 3 initiation in Q1 2010.
• Licensed SUMAVEL DosePro to Desitin Pharma for commercialization in Europe. Desitin completed the pivotal registration study for SUMAVEL DosePro and filed for approval in Europe in October 09.
• July 09, the U.S. FDA approved the NDA for SUMAVEL DosePro
• August 09, signed U.S. co-promotion agreement with Astellas Pharma U.S.
• January 2010 U.S. launched SUMAVEL DosePro with Zogenix Neurology Sales force and Astellas Pharma Primary Care Physician Sales force.

The winners will be announced at an awards ceremony on Tuesday, January 26 at the Drug Delivery Partnerships International Conference.

Share this article with your social network, just click below to share now!

Share |

2010 DDP Awards: Partnering Excellence Nominee: Ranbaxy Labs

Partnership: Excellence in company partnering strategies

The in-licensing team headed by Dr. Harvinder Popli has entered into 44 agreements in the last 5 years of operation. In-licensing as a function started in Ranbaxy in 2005. The agreements have been signed with innovation/technology driven companies from US, Europe and Asia. The deals were done primarily for the Indian market along with markets like Singapore, Malaysia, Vietnam, Cambodia, Myanmar, Philippines, Sri Lanka & in the Middle East region. The deals were signed in therapy areas of Clinical Dermatology, Asthetic Dermatology, CNS, Urology, Oncology, Pain Management, Neutraceuticals, Dental products, Respiratory etc. The in-licensing team is also responsible for pre-launch and project management activities for launching the licensed products within stipulated timelines. As a recognition to her unmatched passion and hard work, recently Dr. Harvinder Popli has been nominated as one of the top 20 business development professionals in the reputed European Business Development newsletter, EuroPlx Business Developer Nov/Dec'2009 edition; weblink.

The winners will be announced at an awards ceremony on Tuesday, January 26 at the Drug Delivery Partnerships International Conference.

Share this article with your social network, just click below to share now!

Share |

2010 DDP Awards: Technology Innovation Nominee: Wallace H. Coulter Center for Translational Research, University of Miami

Technology: a novel Nanoparticle which offers unique targeted in vivo delivery of nucleic acids into Antigen Presenting Cells (APC) resulting in robust / protective immune responses.

The platform is not only ideal for “Genetic Vaccination” as it targets APC and activates helper T cells, it, incidentally, may be used as delivery of nucleic acids including siRNA into such mononuclear cells which has broad therapeutic applications. Wallace H. Coulter Center of the University of Miami is a technology development center for biomedical innovation. WHCC is unique in acting as a catalyst for moving innovative University of Miami research with commercial potential from the bench to industry.

The winners will be announced at an awards ceremony on Tuesday, January 26 at the Drug Delivery Partnerships International Conference.

Share this article with your social network, just click below to share now!

Share |

2010 DDP Awards: Technology Innovation Nominee: Pradama, Inc.

Technology: Novel bone-targeting drug delivery technology

Pradama Inc. is a pharmaceutical company that creates multiple products for bone diseases and disorders using its novel bone-targeting drug delivery technology. Bone tissue is distinguished from other tissues by the presence of bone mineral, mainly hydroxyapatite. Pradama's bone-targeting agents have significant affinity for hydroxyapatite. Pradama’s bone-targeting agents have several advantages over other bone-targeting approaches, including; oral availability, therapeutic inactivity, stability and flexibility.


The winners will be announced at an awards ceremony on Tuesday, January 26 at the Drug Delivery Partnerships International Conference.

Share this article with your social network, just click below to share now!

Share |

2010 DDP Awards: Technology Innovation Nominee: Isis Biopolymer

Technology: IsisIQ™ Patch

Isis Biopolymer, Inc., founded in 2006, is led by a team of experienced scientists and entrepreneurs accomplished at successful development and commercialization of medical devices, materials and systems design. The company has developed a major advance in intelligent non-invasive transdermal drug delivery, the IsisIQ™ Patch. The patch is a fully programmable, single-use, “band-aid-like” active patch that controls and monitors transdermal drug delivery; ensuring safe and accurate administration through the skin using iontophoresis. An innovative solution to the challenges of today’s transdermal drug delivery systems, the IsisIQ™ Patch features a proprietary selective barrier membrane that facilitates the transport or complete cessation of drug molecules through the skin. Drug transport can be modulated for up to three drugs per patch and is fully programmable for customized delivery and monitoring via an integrated wireless communication platform. The unique single electrode design eliminates variability in drug delivery that can occur with changes in the skin due to temperature, moisture and movement; preventing inadvertent or over delivery of drug. The IsisIQ™ Patch is also a biosensor that can detect skin emanations, which may be indications of medical events such as heart attached, shock or diabetic reactions. Breakthroughs in pliable polyester substrate and hydrogels support lower cost development and manufacturing, as well as a more diverse range of delivery of drugs than is currently available. Moving forward, Isis Biopolymer technology will expand the worldwide multi-billion dollar market for transdermal delivery of existing and drugs in development for pain management, oncology, neurology, endocrinology, cardiovascular, CNS disorders, as well as therapies for chronic and acute conditions. Isis Biopolymer has developed not only the technology to revolutionize transdermal drug delivery, but also make it affordable as a result of our materials and manufacturing processes based here in the United States. Isis is focused on providing revolutionary (and cost-effective) transdermal drug delivery and biosensors to improve patient compliance and generate better health care outcomes.

The winners will be announced at an awards ceremony on Tuesday, January 26 at the Drug Delivery Partnerships International Conference.

Share this article with your social network, just click below to share now!

Share |

2010 DDP Awards: Partnering Excellence Nominee: Partners in Care

Partnership: Partnering across the health value chain

Partners in Care has used technology to identify gaps in care, communicate the adherence/persistence needs in chronic care to providers and suppliers, and produce exemplary results in total health management. Where others thought disease management could deliver, Partners in Care showed that patient centered care, through PCMH as well as Care Coordination Entities (expanded care teams armed with data and solutions), could deliver a better dividend that mattered to the patient, the employer and the health plan. They can create these replicable and sustainable results to drive value and increase financial strength across the entire supply chain. That drives value to the demand side of the chain, and THAT drives value across the whole health value chain--promoting individual health, physician competence, and community health.

The winners will be announced at an awards ceremony on Tuesday, January 26 at the Drug Delivery Partnerships International Conference.

Share this article with your social network, just click below to share now!

Share |

2010 DDP Awards: Technology Innovation Nominee: University of California at San Francisco

Electron tomography and image reconstruction technology to field monitor and determine the structure of highly dynamic proteins, such as antibodies, high-density lipoproteins and low-density lipoproteins Antibodies have been used as a drug delivery vehicle for years. With the drugs bonding to antibodies as the conjugated antibody, some conjugated antibodies may lose their function to bond to the target cell. To discover the reason for improving the drug delivery efficiencies, the structure of the conjugate is usually needed. However, structural determination of the dynamic antibody is not available by current technology, so we developed the electron tomography and image reconstruction technology which allow us to determine each individual antibody structure at about 10A resolution. By using this technology, we have discovered the conformational change of the antibodies after being bound to drug. Thus, this method has a general impact to field monitor and determine the structure of highly dynamic proteins, such as antibodies, high-density lipoproteins and low-density lipoproteins.

The winners will be announced at an awards ceremony on Tuesday, January 26 at the Drug Delivery Partnerships International Conference.

Share this article with your social network, just click below to share now!

Share |

2010 DDP Awards Nominee: Technology Innovation Nominee: Elan Drug Technologies

Elan Drug Technologies’ NanoCrystal® technology is truly one of the most successful drug delivery technology innovations in the past ten years. Designed to overcome issues associated with poor water solubility, ten years since its first filing with the FDA, it has gone on to achieve product in-market sales for clients in excess of $7.8B.

Five products are now launched in over 100 territories worldwide incorporating this technology. Rapamune® (Wyeth) immunosuppressant, which was launched in 2001, eliminated need for refrigeration of tablet product and provided a 23% improvement in bioavailability. Emend® (Merck) was launched in 2003 for the treatment of nausea and vomiting with a 600% improvement in bioavailability, the product was successfully launched in Japan at end of 2009. TriCor® 145, which provided improved bioavailability and minimal food effect, was launched by Abbott in 2004. Megace ES®,, for cachexia in AIDS patients, was launched in 2005 with a 28% improvement in bioavailability, with a free from food effect. In August 2009, the first once- monthly schizophrenic injectable depot formulation, INVEGA® Sustenna™, was launched by Janssen using this technology.

Since 2001, 11 products using our technologies have been launched for our clients in over 100 countries worldwide, making us the most successful drug delivery company in the past decade. We believe more than any other drug delivery company we have developed superior, commercially successful technologies for our clients.

The winners will be announced at an awards ceremony on Tuesday, January 26 at the Drug Delivery Partnerships International Conference.

Share this article with your social network, just click below to share now!

Share |

Where would you like to attend Drug Delivery Partnerships 2010?

Even though Drug Delivery Partnerships 2010 is just around the corner, we're beginning to play DDP 2011! We're in Orlando, Florida, this year, but would like your input on where you'd like to attend next year! We invite you to participate in our poll.


This is the global drug delivery partnerships meeting place, focusing on bringing together professionals seeking the latest strategies, industry updates, and networking opportunities to help position your company for a successful partnership/collaboration. Join us today on LinkedIn or Follow us on Twitter! For more on the Drug Delivery Partnerships event, visit the website: http://bit.ly/6chdrj Download the 2010 Drug Delivery Partnerships Brochure: http://bit.ly/8DRnHv

Share this article with your social network, just click below to share now!

Share |